He Yongkang, He Xiaofeng
Department of Infectious Diseases, Taixing People's Hospital, Taizhou, China.
Yonsei Med J. 2019 Mar;60(3):267-276. doi: 10.3349/ymj.2019.60.3.267.
Hepatocellular carcinoma (HCC) is a highly aggressive malignant tumor, the prognosis of which remains poor. Recently, microRNAs have been reported to play crucial functions in multiple tumors, including HCC. However, the molecular mechanisms of miR-370 in HCC still remain largely unknown. The present study focused on the effects of miR-370 on HCC migration, invasion, and epithelial-mesenchymal transition (EMT).
We investigated the key roles and possible regulatory mechanism of miR-370 in regulating HCC metastasis with functional assays, such as transwell assay. Quantitative real-time PCR (qRT-PCR) was used to detect miR-370 and guanylylcyclase domain containing 1 (GUCD1) expression in HCC tissues and cells. Subsequently, we performed transwell assays to determine the functions of miR-370 in HCC cell invasion and migration. Western blot was used to determine protein expressions of relevant genes. Luciferase reporter assays were conducted to confirm the target gene of miR-370.
qRT-PCR analysis demonstrated that miR-370 was dramatically downregulated in HCC. Moreover, downregulated miR-370 was found to be associated with poor survival and adverse clinicopathologic characteristics of HCC patients. Transwell assays revealed that miR-370 overexpression dramatically suppressed HCC invasion and migration. Meanwhile, miR-370 restoration prominently inhibited EMT progression in HCC cells. Luciferase reporter assays confirmed as a downstream target gene of miR-370. GUCD1 expression in HCC tissues was prominently increased and inversely correlated with miR-370 expression. Furthermore, GUCD1 was verified as mediating the suppressive influence of miR-370 on cell metastasis and EMT in HCC.
Taken together, our study confirmed that miR-370 suppressed HCC cell metastasis and EMT via regulating . Accordingly, the miR-370/GUCD1 axis may potentially acts as attractive therapeutic targets and novel biomarkers for HCC treatment.
肝细胞癌(HCC)是一种侵袭性很强的恶性肿瘤,其预后仍然很差。最近,有报道称微小RNA在包括HCC在内的多种肿瘤中发挥关键作用。然而,miR-370在HCC中的分子机制仍 largely未知。本研究聚焦于miR-370对HCC迁移、侵袭和上皮-间质转化(EMT)的影响。
我们通过功能试验,如Transwell试验,研究miR-370在调节HCC转移中的关键作用和可能的调控机制。采用定量实时PCR(qRT-PCR)检测HCC组织和细胞中miR-370和含鸟苷酸环化酶结构域1(GUCD1)的表达。随后,我们进行Transwell试验以确定miR-370在HCC细胞侵袭和迁移中的功能。蛋白质印迹法用于测定相关基因的蛋白表达。进行荧光素酶报告基因试验以确认miR-370的靶基因。
qRT-PCR分析表明,miR-370在HCC中显著下调。此外,发现miR-370下调与HCC患者的不良生存和不良临床病理特征相关。Transwell试验显示,miR-370过表达显著抑制HCC侵袭和迁移。同时,miR-370恢复显著抑制HCC细胞中的EMT进展。荧光素酶报告基因试验证实 为miR-370的下游靶基因。HCC组织中GUCD1表达显著增加,且与miR-370表达呈负相关。此外,证实GUCD1介导miR-370对HCC细胞转移和EMT的抑制作用。
综上所述,我们的研究证实miR-370通过调节 抑制HCC细胞转移和EMT。因此,miR-370/GUCD1轴可能潜在地作为HCC治疗有吸引力的治疗靶点和新型生物标志物。 (注:原文中部分内容缺失,已按原样翻译)